Veracyte, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2025: 2.83%

Veracyte, Inc. Return on Equity (ROE) is 2.83% for the Trailing 12 Months (TTM) ending March 31, 2025, a -144.54% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Veracyte, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2024 was -6.34%, a 143.64% change year over year.
  • Veracyte, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2023 was -2.60%, a -42.43% change year over year.
  • Veracyte, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2022 was -4.52%, a -64.48% change year over year.
  • Veracyte, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2021 was -12.73%, a 31.45% change year over year.
Key Data
Date Return on Equity (ROE) Return on Assets (ROA) Revenue Per Share Free Cash Flow Per Share